News | May 11, 2015

Provision Healthcare to Develop First Proton Therapy Center in Northern China's Free Trade Zone

Partner agreement will build proton center with SC360 system plus training facility

May 11, 2015 — Provision Healthcare has signed a joint agreement with the Tianjin Taishan Cancer Hospital (International Personalized Cancer Center, “IPCC”) in northern China to build the first and only proton therapy center in the free trade zone. The agreement will also develop a training facility for medical providers as part of Provision’s global expansion strategy.

The $100 million center will be jointly owned and operated by Provision and Tianjin Hospital and named the TAEA Sino-US Proton Treatment and Research Center. ProNova Solutions, Provision’s research and development (R&D) and manufacturing business, will manufacture and outfit the center’s three treatment rooms with its SC360 proton treatment system. The project is scheduled for completion in early 2018.

Proton therapy uses a single beam of high-energy protons to precisely target a tumor with limited exposure to surrounding healthy tissues. Proton therapy is used to treat a variety of cancer types including prostate, breast, lung, head and neck, pediatric cancer and Hodgkin’s lymphoma.

The venture will include a research capability for conducting clinical trials focused on further development of proton therapy in northern China. Additionally, the partners will develop and build a nearby training center to educate medical personnel as the use of proton therapy expands across the country.

“As the name indicates, Tianjin Taishan Hospital (IPCC) strives to provide personalized cancer treatment,” said Xishan Hao, M.D., president of the Chinese Anti-Cancer Association, honorary president of Tianjin Medical University and Tianjin Medical University Cancer Institute and Hospital, director of the Tianjin Cancer Institute. “ProNova’s advanced technology will help Tianjin Taishan Hospital become the first provider for proton therapy in a free trade zone of China. The network of proton therapy centers that Provision has created will bring Taishan to the front row of global cancer research.”

The proton center’s three treatment rooms will include two 360-degree rotation gantrys and one fixed beam system, and Provision will be responsible for operation and maintenance of the equipment. Provision will be involved in design and development of the project as well as management of patient services.

For more information: www.provisionha.com

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Overlay Init